Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences GAAP operating margin: -133.2% in Q2 2026, down 168.1 pts from a year earlier. That is the lowest of the 39 quarters on record here.
Latest, Q2 2026
-133.2%
Period ended Jun 30, 2026
Change on a year earlier
-168.1 pts
34.9% in Q2 2025
History
39 quarters
Since Q4 2016
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
“|| GAAP operating margin | (133.2) | % | 34.9 | % | (52.9) | % | 34.3 | %”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 8-K GAAP to Non-GAAP Reconciliation.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences GAAP operating margin (%), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gaap-op-margin-pct
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.